Indirect treatment comparison of durvalumab plus carboplatin/paclitaxel followed by durvalumab plus olaparib versus pembrolizumab plus carboplatin/paclitaxel followed by pembrolizumab as first-line treatment for mismatch repair proficient endometrial cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Larissa Alejandra Meyer, Birutė Brasiūnienė, Marta Gil-Martin, Dagmara Klasa-Mazurkiewicz, Kathleen N. Moore, Jalid Sehouli, Ayelet Shai, Shannon Neville Westin, Jack Williams, Abdul-Azeez Ganiyu, Dan James, Zacharie Mbanya
+2 more Marta Vargas Gomes, Els Van Nieuwenhuysen
DOI: 10.1016/j.ijgc.2025.103493
Cited by: 0

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103493–103493
Publication date
1 February 2026
Language
EN